Market Research Future published a research report on Asia Pacific Skin Cancer Market and report begins with the overview of Industry structure, and describes industry environment, then analyses market size, share and forecast up to 2023. Asia Pacific Skin Cancer Market Report also gives in-depth qualitative observations, historical data, and identifiable projections about market. Report Provide detailed information on the possible segments and sub segments of the market and its regional analysis.
The prevalence of skin cancer is increasing owing to depleting ozone level and increasing solar UV radiation entering the Earth’s surface. According to the WHO, it is estimated that a 10% decrease in the ozone level is likely to result in an additional 300,000 non-melanoma and 4,500 melanoma skin cancer cases.
The major driving factor for the growth of the market is increasing the prevalence of skin cancer. Furthermore, extensive R&D pipelines and increasing usage of combination therapies have fueled the growth of the market. On another hand, stringent regulatory guidelines, side effects associated with the treatment and long approval time for the drugs may hamper the growth of the market over the review period.
Asia Pacific Skin Cancer Market is expected to grow at a CAGR of 8.8% during the forecasted period.
Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/1173
Key Players for Asia Pacific Skin Cancer Market
Some of the key players in the market:
F. Hoffmann-la Roche Ltd. (Switzerland), Novartis International AG (Switzerland), Sun Pharma Industries Ltd. (India), Elekta AB (Sweden), Varian Medical Systems Inc. (US), Cannabis Science Inc. (US), Cellceutix Corp. (US), LEO Pharma A/S (Denmark), Moberg Pharma AB (Sweden), Mylan Pharmaceutical Inc. (US), Oncothyreon Inc. (US), Eli Lilly and Co. (US), Bristol Myers Squibb Co. (US), Boehringer Ingelheim GmbH (Germany), Aqua Pharmaceuticals LLC (US), Valeant Pharmaceuticals Inc (Canada), Meda AB (US), iCAD Inc. (Sweden), and Merck & Co. Inc. (US).
Regional Analysis for Asia Pacific Skin Cancer Market
On the regional basis, Asia Pacific market is segmented into Japan, India, China, the Republic of Korea, Australia, and the Rest of Asia Pacific.
Asia Pacific is the fastest growing skin cancer market. Japan, Australia, and China are the major contributor to the market growth. The incidence of skin cancer per 100,000 population is 20-25 cases in Japan, 11-12 cases in China. About 80% of the cases are basal cell carcinoma (BCC), 16% squamous cell carcinoma, and 4% are melanoma.
Continuously increasing the prevalence of skin cancer in Japan is driving the growth of this region. Furthermore, increasing government support for research and continuous development in technology is an important driving factor for the growth of the Asia Pacific market.
Segments for Asia Pacific Skin Cancer Market
The Asia Pacific skin cancer market is segmented on the basis of type, treatment, and end users.
On the basis of the type, it is segmented into basal cell carcinoma, squamous-cell carcinoma, and melanoma.
On the basis of the treatment, it is segmented into non-invasive, chemotherapy, surgical, and other. Furthermore, non-invasive treatments are segmented into laser therapy, radiotherapy, photodynamic therapy, cryotherapy, and others. The chemotherapy is further segmented into systemic and targeted. The surgical treatment is segmented into photodynamic therapy, cryosurgery, Mohs micrographic surgery, and others.
On the basis of end users, the market is segmented into hospital and clinics, diagnostic centers, cancer research institute, and other.
Get Prime Discount on Report @ https://www.marketresearchfuture.com/check-discount/1173
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Hadapsar, Pune – 411028
Phone: +1 646 845 9312